Timoprazole is in a class of medications called proton pump inhibitors (PPI) that inhibit gastric acid secretion. While it has never come to market, it was studied early on and is considered to be the "backbone" of the PPI class that succeeded it.[1][2] This medication has high anti-secretory activity, which flared interest along with its simple structure.[3]

Timoprazole
Identifiers
  • 2-[(2-Pyridylmethyl)sulfinyl]-1H-benzimidazole
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H11N3OS
Molar mass257.31 g·mol−1
3D model (JSmol)
  • n1ccccc1CS(=O)c2[nH]c3ccccc3n2
  • InChI=1S/C13H11N3OS/c17-18(9-10-5-3-4-8-14-10)13-15-11-6-1-2-7-12(11)16-13/h1-8H,9H2,(H,15,16) checkY
  • Key:HBDKFZNDMVLSHM-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ Snaeder W (1996). Drug prototypes and their exploitation. Wiley. pp. 414–5.
  2. ^ Hemenway JN (2007). "Case Study: Omeprazole (Prilosec)". Prodrugs. Biotechnology: Pharmaceutical Aspects. pp. 1313–21. doi:10.1007/978-0-387-49785-3_49. ISBN 978-0-387-49782-2.
  3. ^ Senn-Bilfinger J, Sturm E (2006). "The Development of a New Proton-Pump Inhibitor: The Case History of Pantoprazole". Analogue-based Drug Discovery. pp. 115–36. doi:10.1002/3527608001.ch6. ISBN 978-3-527-60800-3.